Aurobindo Pharma subsidiary launches generic Advair Diskus in US
Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US. This is the first product from the company's inhalation pipeline to be commercialized in the US market. The product is available in two strengths for treating asthma and COPD.
The launch of a generic version of a significant drug like Advair Diskus® can contribute to revenue growth and market share, but the overall impact will depend on market penetration and competition.
The launch of a new generic product in a major market like the US is a positive development for the company, indicating progress in its product pipeline and market expansion.
Lannett Company LLC, a wholly owned stepdown subsidiary of Aurobindo Pharma USA, Inc., has launched the generic equivalent of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in the US market. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in the US. The product is available in 100/50 mcg and 250/50 mcg strengths. Advair Diskus® in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This launch aligns with Aurobindo's strategy to expand its portfolio of complex and differentiated inhalation products.
A plain-language summary of a public exchange filing by Aurobindo Pharma Limited. Read the original for the full detail.